<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583492</url>
  </required_header>
  <id_info>
    <org_study_id>Prostate4809</org_study_id>
    <nct_id>NCT00583492</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Suicide Gene Therapy and Prostate Cancer</brief_title>
  <acronym>ReCAP</acronym>
  <official_title>A Randomized, Controlled Trial of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy in Combination With IMRT Versus IMRT Alone for the Treatment of Newly-Diagnosed Prostate Cancer With an Intermediate Risk Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled trial that will test the hypothesis that
      replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy
      intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80
      Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk
      profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES

      This is a randomized, controlled trial that will test the hypothesis that
      replication-competent adenovirus-mediated suicide gene therapy in combination with 80 Gy
      intensity modulated radiotherapy (IRMT)will improve freedom from failure (FFF) relative to 80
      Gy IMRT alone in patients with newly-diagnosed prostate cancer with an intermediate-risk
      profile.

      The trial contains two treatment arms:

      Arm 1- Gene Therapy + IMRT Arm 2- IMRT

      The study will be stratified by clinical site and pre-treatment risk factors (e.g., %
      positive biopsy cores, Gleason score.

        -  Gleason score 5/6 AND PSA &lt;10 ng/mL; AND &gt;=50% positive biopsy cores

        -  (Gleason score 5/6 and PSA 10-20 ng/mL) OR (Gleason score 7 and PSA 0 - 20 ng/mL); AND
           &lt;50% positive biopsy cores

        -  Gleason score 5/6 and PSA 10-20 ng/mL) OR (Gleason score 7 and PSA 0-20 ng/mL) AND &gt;=50%
           positive biopsy cores.

      An interim safety analysis (Interim Analysis 1) will be conducted after the first 21 patients
      in the investigational therapy arm, and a total of 42 subjects in both arms, have completed
      the 90 day toxicity assessment following randomization (phase 2 component). If, at this
      point, there are no safety concerns as determined by the Data and Safety Monitoring Board
      (DSMB), the trial will continue as a phase 3 study with two additional interim analyses
      (Interim Analyses 2 &amp; 3). The primary analysis for treatment efficacy will be based on all
      randomized subjects.

      Primary

      To assess the relative efficacy of replication-competent adenovirus-mediated suicide gene
      therapy in combination with 80 Gy intensity modulated radiotherapy (IMRT) versus 80 Gy IMRT
      alone in patients with newly-diagnosed prostate cancer with an intermediate-risk profile. The
      primary endpoint is freedom from failure (FFF) (biochemical or clinical).

      Secondary

      To assess the difference between the two treatment arms for:

        -  Acute (&lt;= 90 days) and long-term (&gt; 90 days) toxicity.

        -  Prostate biopsy status (12 cores) at 2 years.

        -  Freedom from distant metastases.

        -  Disease-specific and overall survival.

        -  Quality of life.

      Exploratory

      To examine:

        -  Possible effect of gene therapy on PSA doubling time (PSADT) after PSA failure.

        -  Possible association between the primary and secondary outcomes and
           Ad5-yCD/mutTKSR39rep-ADP adenovirus persistence (as measured by adenoviral DNA in
           blood).

        -  Possible association between the primary and secondary outcomes and specific
           immunological endpoints including levels of circulating CD4+ and CD8+ T lymphocytes,
           T-cell proliferation response, cytotoxic T lymphocyte (CTL) response, and development of
           antibodies to prostate-specific antigens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom From Biochemical/Clinical Failure (FFF)</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical/Clinical Failure was defined as PSA nadir plus 2 ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute &gt;= Grade 3 Treatment-related Toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>This metric includes both expected and unexpected events Toxicities were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Prostate Biopsy at 2 Years</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Distant Metastases</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific Survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Quality of Life</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of Life was measured using the comprehensive Expanded Prostate Cancer Index Composite (EPIC) instrument 19 and 20</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ad5-yCD/mutTKSR39rep-ADP + IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gene Therapy + IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad5-yCD/mutTKSR39rep-ADP</intervention_name>
    <description>Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
    <arm_group_label>Ad5-yCD/mutTKSR39rep-ADP + IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
    <arm_group_label>IMRT Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with histologically-confirmed adenocarcinoma of the prostate within 180 days prior
             to registration. To be eligible, the subjects must have one of the following
             conditions:

               -  Stage T1 or T2, Gleason Score 7, PSA &lt;= 20 ng/mL, Any number positive biopsy
                  cores

               -  Stage T1 or T2, Gleason Score 5 or 6, PSA &gt;=10 ng/mL and &lt;20 ng/mL, Any number
                  positive biopsy cores

               -  Stage T1 or T2, Gleason Score 5 or 6, PSA &lt;10 ng/mL and &gt;=50% positive biopsy
                  cores

          -  Negative lymph nodes as established by imaging, nodal sampling, or dissection within
             90 days prior to registration.

          -  No evidence of metastatic disease as evaluated by bone scan and CT scan of the abdomen
             and pelvis within 90 days prior to registration

          -  Karnofsky performance status &gt;=70

          -  Subjects must have adequate baseline organ function, as assessed by the following
             laboratory values, within 30 days before initiating the study

          -  Adequate renal function with serum creatinine &lt;=1.5 mg/dL or creatinine clearance &gt;=45
             mL/min/m2.

          -  Platelet count &gt; 100,000/μL.

          -  Absolute neutrophil count &gt; 1,000/μL.

          -  Hemoglobin &gt; 10.0 g/dL.

          -  Normal partial thromboplastin time (PTT) and prothrombin (PT).

          -  Bilirubin &lt; 1.5 mg/dL; SGOT and SGPT &lt; 2.5 times upper limit of normal (ULN).

          -  Men of child-producing potential must be willing to consent to use effective
             contraception while on treatment and for at least 3 months afterwards.

          -  Subjects must possess the ability to give informed consent and express a willingness
             to meet all of the expected requirements of the protocol for the duration of the
             study.

        Exclusion Criteria:

        Subjects with the following conditions will be excluded from the study:

          -  Stage &gt;= T3.

          -  Prostate specific antigen (PSA) &gt; 20 ng/mL.

          -  Gleason score &gt;= 8.

          -  Prostate volume &gt;120cc.

          -  Pathologically positive lymph nodes or nodes &gt; 1.5 cm on imaging. Note: nodes &gt; 1.5 cm
             but biopsy negative are allowed.

          -  Evidence of M1 metastatic disease.

          -  Prior invasive malignancy except for non-melanoma skin cancer within 5 years of
             enrollment.

          -  Prognosis for survival of &lt; 5 years.

          -  Prior radical prostatectomy, cryosurgery for prostate cancer, or bilateral orchiectomy
             for any reason.

          -  Prior radiotherapy, including brachytherapy, to the region of the study cancer that
             would result in overlap of radiation fields.

          -  Prior or planned androgen suppression therapy or prior systemic chemotherapy for the
             study cancer. Note that prior chemotherapy for a different cancer is allowed; however,
             patients must be &gt;2 years post-completion of chemotherapy at time of registration.
             Patients on Proscar therapy must stop to be eligible.

          -  Severe, active co-morbidity defined as:

          -  Unstable angina and/or congestive heart failure requiring hospitalization within the
             last 6 months.

          -  Transmural myocardial infarction within the last 6 months.

          -  Acute infection. Acute infection is defined by any viral, bacterial, or fungal
             infection that requires specific therapy within 72 hours of initiation of the study
             therapy.

          -  Positive serological test for HIV at baseline.

          -  Previous history of liver disease including hepatitis.

          -  Immunosuppressive therapy including systemic corticosteroids. Use of inhaled and
             topical corticosteroids is permitted.

          -  Impaired immunity or susceptibility to serious viral infections.

          -  Allergy to any product used in the protocol. (If the subject has an allergy to
             Ciprofloxacin, another antibiotic can be substituted at the discretion of the treating
             physician.

          -  Serious medical or psychiatric illness or concomitant medication, which, in the
             judgment of the principal investigator, might interfere with the subject's ability to
             respond to or tolerate the treatment or complete the trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Movsas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, Aguilar-Cordova E, Kim JH. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002 Sep 1;62(17):4968-76.</citation>
    <PMID>12208748</PMID>
  </reference>
  <reference>
    <citation>Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M, Kim JH. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther. 2007 Mar;15(3):636-42. Epub 2007 Jan 16.</citation>
    <PMID>17228316</PMID>
  </reference>
  <reference>
    <citation>Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003 Nov 1;63(21):7497-506.</citation>
    <PMID>14612551</PMID>
  </reference>
  <reference>
    <citation>Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther. 2007 May;15(5):1016-23. Epub 2007 Mar 20.</citation>
    <PMID>17375076</PMID>
  </reference>
  <results_reference>
    <citation>Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F, Barton K, Pegg J, Zhang Y, Cheng J, Oja-Tebbe N, Bourgeois R, Gupta N, Lane Z, Rodriguez R, DeWeese T, Movsas B. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76. doi: 10.1016/j.ijrobp.2014.02.034. Epub 2014 May 5.</citation>
    <PMID>24837889</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <results_first_submitted>April 13, 2015</results_first_submitted>
  <results_first_submitted_qc>February 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2016</results_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Benjamin Movsas, M.D.</investigator_full_name>
    <investigator_title>Chairman, Department of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Prostatic Neoplasms</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Adenocarinomas</keyword>
  <keyword>Tumors of the Prostate</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gene Therapy + IMRT</title>
          <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
        </group>
        <group group_id="P2">
          <title>IMRT Alone</title>
          <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gene Therapy + IMRT</title>
          <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
        </group>
        <group group_id="B2">
          <title>IMRT Alone</title>
          <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Freedom From Biochemical/Clinical Failure (FFF)</title>
        <description>Biochemical/Clinical Failure was defined as PSA nadir plus 2 ng/mL</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Biochemical/Clinical Failure (FFF)</title>
          <description>Biochemical/Clinical Failure was defined as PSA nadir plus 2 ng/mL</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute &gt;= Grade 3 Treatment-related Toxicity</title>
        <description>This metric includes both expected and unexpected events Toxicities were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Acute &gt;= Grade 3 Treatment-related Toxicity</title>
          <description>This metric includes both expected and unexpected events Toxicities were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3</description>
          <units>percentage of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Prostate Biopsy at 2 Years</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Prostate Biopsy at 2 Years</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Distant Metastases</title>
        <time_frame>10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Distant Metastases</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-specific Survival</title>
        <time_frame>10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-specific Survival</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Quality of Life</title>
        <description>Quality of Life was measured using the comprehensive Expanded Prostate Cancer Index Composite (EPIC) instrument 19 and 20</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gene Therapy + IMRT</title>
            <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10e12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
          </group>
          <group group_id="O2">
            <title>IMRT Alone</title>
            <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Quality of Life</title>
          <description>Quality of Life was measured using the comprehensive Expanded Prostate Cancer Index Composite (EPIC) instrument 19 and 20</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gene Therapy + IMRT</title>
          <description>Gene Therapy + IMRT
Ad5-yCD/mutTKSR39rep-ADP: 1 x 10^12 sterile injectable solution, 1 injection on day one Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy</description>
        </group>
        <group group_id="E2">
          <title>IMRT Alone</title>
          <description>IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Low neutrophil counts</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Low platelets</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <description>Increased SGOT/SGPT</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Movsas</name_or_title>
      <organization>Henry Ford Health System</organization>
      <phone>313-516-2319</phone>
      <email>bmovsas1@hfhs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

